

EQA round: RFA1/25 - Risk Factors for Atherosclerosis

Deadline: 4.4.2025

Setup: groups - M (measurement principle); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
(114) Apolipoprotein AI	[g/L]				12							12	10	83
Sample A												12	11	92
(2) Immunoturbidimetry		1,43	0,12	8,4	12	0	CVP	1,42	0,025	17%	1,17	1,67	12	
Sample B												12	11	92
(2) Immunoturbidimetry		2,18	0,25	11	12	0	CVP	2,18	0,039	17%	1,8	2,56	12	
(115) Apolipoprotein B	[g/L]				15							15	13	87
Sample A												15	14	93
(2) Immunoturbidimetry		0,868	0,043	5	15	0	CVP	0,863	0,011	14%	0,742	0,984	15	
Sample B												15	13	87
(2) Immunoturbidimetry		1,28	0,097	7,6	15	0	CVP	1,27	0,016	14%	1,09	1,45	15	
(111) Cholesterol	[mmol/L]				40							40	38	95
Sample A												40	39	98
(0) Not specified		4,64	0,16	3,4	40	0	CVP	4,62	0,018	8%	4,25	4,99	40	
Sample B												40	39	98
(0) Not specified		7	0,26	3,6	40	0	CVP	6,94	0,025	8%	6,38	7,5	40	
(113) Cholesterol HDL	[mmol/L]				40							40	39	98
Sample A												40	40	100
(2) Direct determination		1,27	0,043	3,4	40		CVP	1,29	0,008	15%	1,09	1,49	40	
Other		1,27	0,044	3,5	39	0						39		
					1	0						1		
							1x 1							
Sample B												40	39	98
(2) Direct determination		1,96	0,076	3,9	40		CVP	1,98	0,014	15%	1,68	2,28	39	
Other		1,96	0,078	4	39	0						39		
					1	0						1		
							1x 1							
(118) Cholesterol LDL (direct determination)	[mmol/L]				36							36	35	97
Sample A												36	36	100
(0) Not specified		2,8	0,21	7,4	36	0	CVP	2,81	0,035	20%	2,24	3,38	36	
Sample B												36	35	97
(0) Not specified		4,16	0,39	9,4	36	0	CVP	4,15	0,059	20%	3,32	4,98	36	
(116) Cholesterol LDL (calculation)	[mmol/L]				8							8	8	100
Sample A												8	8	100
(0) Not specified		2,71	0,1	3,8	8	0	CVP	2,74	0,032	15%	2,32	3,16	8	
Sample B												8	8	100
(0) Not specified		4,18	0,24	5,7	8	0	CVP	4,14	0,048	15%	3,51	4,77	8	
(117) Lipoprotein (a) [g/L]	[g/L]				7							7	6	86
Sample A												7	7	100
(2) Immunoturbidimetry		0,235	0,022	9,4	7	0	CVP	0,232	0,005	25%	0,174	0,29	7	
Sample B												7	6	86
(2) Immunoturbidimetry		0,325	0,022	6,8	7	0	CVP	0,324	0,007	25%	0,243	0,405	7	
(119) Lipoprotein (a) [nmol/L]	[nmol/L]				5							5	5	100
Sample A												5	5	100
(2) Immunoturbidimetry		37,9	0,52	1,4	5	0	CVP	39,1	1,2	20%	31,2	47	5	
Sample B												5	5	100
(2) Immunoturbidimetry		53,6	2,1	3,9	5	0	CVP	56,1	1,4	20%	44,8	67,4	5	
(112) Triacylglycerols	[mmol/L]				39							39	38	97
Sample A												39	39	100
(1) Photometric enzyme (GPO-PAP)		1,37	0,047	3,4	39		CVP	1,38	0,008	15%	1,17	1,59	39	
Other		1,37	0,048	3,5	36	0						36		
					3	0						3		
							3x 2							
Sample B												39	38	97
(1) Photometric enzyme (GPO-PAP)		1,95	0,06	3,1	39		CVP	1,97	0,009	15%	1,67	2,27	36	
Other		1,95	0,063	3,2	36	0						36		
					3	0						3		
							3x 2							